HOME >> MEDICINE >> NEWS
JCI table of contents, 1 August 2003

https://www.the-jci.org/press/17864.pdf


Increasing tolerance to contact allergens

Common contact allergies are triggered by allergens that affect the skin such as poison oak, poisin ivy, latex, dyes, fragrances, and metals. Researchers at the University of Mainz, Germany, have now shown that IL-10, a critical mediator of the immune response, is required in order to build-up tolerance to such allergens. The authors achieve what is known as low zone tolerance (LZT), in which repeated applications of low doses of contact allergens hinders the development of the allergic reaction. They demonstrate that mice lacking IL-10 cannot achieve LZT to allergens, suggesting that this IL-10driven response may be utilized in allergic therapies.

TITLE: Critical role of IL-10 in the induction of low zone tolerance to contact allergens

AUTHOR CONTACT:
Kerstin Steinbrink
University of Mainz, Mainz, Germany.
Phone: 49-6131-17-2297
Fax: 49-6131-17-6614
E-mail: steinbrink@hautklinik.klinik.uni-mainz.de

View the PDF of this article at: https://www.the-jci.org/press/18106.pdf


OutFoxing obesity

Obesity results from a massive expansion of fat cells. This expansion involves the differentiation of early precursor fat cells, known as preadipocytes, into mature fat cells. Researchers at Rockefeller University in New York have revealed that preadipocytes stably expressing the Foxa-2 protein do not differentiate into mature fat cells. Furthermore, in multiple rodent models of obesity they observed that Foxa-2 production is increased, in what may be an important counterregulatory mechanism to prevent the expansion of fat cell numbers. While the stimuli that induce Foxa-2 expression in mature fat cells is unknown, the authors propose that the pathways inv
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Portable system offers dialysis patients liberating changes
2. Milk, fruits and vegetables may help reduce disability risk
3. Parents comfortable with vaccination for sexually transmitted infections for adolescent children
4. JCI table of contents, January 20 2005
5. Most adverse events in hospitalized children are preventable
6. Study finds no reduction in breast cancer risk with consumption of vegetables and fruits
7. Requip tablets treat symptoms of primary RLS
8. Medical negligence system is secretive, unaccountable and unregulated
9. Spina bifida: 70% of cases preventable by folic-acid supplementation
10. Determining which pancreatic cancers are treatable
11. Vegetable lovers should be viewed as different from fruit aficionados

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: